Cargando…
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
INTRODUCTION: Recent studies indicate that bone marrow stromal cells (BMSCs) derived from patients with multiple myeloma (MM) differ from those of healthy donors in their expression of extracellular matrix compounds and in cytokine production. It is not known whether these abnormalities are primary...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Birkhäuser-Verlag
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766495/ https://www.ncbi.nlm.nih.gov/pubmed/18512025 http://dx.doi.org/10.1007/s00005-008-0022-5 |
_version_ | 1782173224381972480 |
---|---|
author | Zdzisińska, Barbara Bojarska-Junak, Agnieszka Dmoszyńska, Anna Kandefer-Szerszeń, Martyna |
author_facet | Zdzisińska, Barbara Bojarska-Junak, Agnieszka Dmoszyńska, Anna Kandefer-Szerszeń, Martyna |
author_sort | Zdzisińska, Barbara |
collection | PubMed |
description | INTRODUCTION: Recent studies indicate that bone marrow stromal cells (BMSCs) derived from patients with multiple myeloma (MM) differ from those of healthy donors in their expression of extracellular matrix compounds and in cytokine production. It is not known whether these abnormalities are primary or are acquired by BMSCs on contact with MM cells. MATERIALS AND METHODS: Interleukin (IL)-6, IL-11, IL-10, and tumor necrosis factor (TNF)-α production by CD166(+) mesenchymal BMSCs and the CD38(+)/CD138(+) RPMI8226 myeloma cell line cultivated in vitro in monocultures or co-cultivated under cell-to-cell contact or non-contact conditions in the presence of a tissue culture insert were measured. Intracellular cytokines were measured by flow cytometry analysis as the percentage of cytokine-producing cells or by mean fluorescence intensity as the level of cytokine expression in cells. Additionally, ELISA was used to measure IL-6, soluble IL-6 receptor (sIL-6R), IL-11, IL-10, TNF-α, B-cell-activating factor of the TNF family (BAFF), hepatocyte growth factor (HGF), and osteopontin (OPN) production in the supernatants of the cultures and co-cultures. RESULTS: A higher ability of the BMSCs of MM patients than in controls was detected to produce IL-6, IL-10, TNF-α, OPN, and especially HGF and BAFF in response to the RPMI8226 cells. Moreover, the BMSCs of the MM patients significantly enhanced the production of sIL-6R by the RPMI8226 cells. DISCUSSION: Cytokines over-expressed by BMSCs of MM patients can function as growth factors for myeloma cells (IL-6, IL-10, HGF), migration stimulatory factors for tumor plasma cells (TNF-α, HGF), adhesion stimulatory factors (HGF, BAFF and OPN), stimulators of osteoclastogenesis (IL-6, TNF-α), and angiogenic factors (TNF-α). The results of this experiment strongly suggest that the BMSCs from MM patients differed in spontaneous and myeloma cell-induced production of cytokines, especially of HGF and BAFF, and these abnormalities were both primary and acquired by the BMSCs on contact with the MM cells. This in turn suggests the presence of an undefined, autocrine stimulation pathway resulting in a prolonged production of cytokines even in long-term cultures in vitro and in vivo. These abnormalities might provide optimal conditions for the proliferation and differentiation of residual tumor cells or their precursors in the affected bone marrow. |
format | Text |
id | pubmed-2766495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Birkhäuser-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-27664952009-10-26 Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells Zdzisińska, Barbara Bojarska-Junak, Agnieszka Dmoszyńska, Anna Kandefer-Szerszeń, Martyna Arch Immunol Ther Exp (Warsz) Original Article INTRODUCTION: Recent studies indicate that bone marrow stromal cells (BMSCs) derived from patients with multiple myeloma (MM) differ from those of healthy donors in their expression of extracellular matrix compounds and in cytokine production. It is not known whether these abnormalities are primary or are acquired by BMSCs on contact with MM cells. MATERIALS AND METHODS: Interleukin (IL)-6, IL-11, IL-10, and tumor necrosis factor (TNF)-α production by CD166(+) mesenchymal BMSCs and the CD38(+)/CD138(+) RPMI8226 myeloma cell line cultivated in vitro in monocultures or co-cultivated under cell-to-cell contact or non-contact conditions in the presence of a tissue culture insert were measured. Intracellular cytokines were measured by flow cytometry analysis as the percentage of cytokine-producing cells or by mean fluorescence intensity as the level of cytokine expression in cells. Additionally, ELISA was used to measure IL-6, soluble IL-6 receptor (sIL-6R), IL-11, IL-10, TNF-α, B-cell-activating factor of the TNF family (BAFF), hepatocyte growth factor (HGF), and osteopontin (OPN) production in the supernatants of the cultures and co-cultures. RESULTS: A higher ability of the BMSCs of MM patients than in controls was detected to produce IL-6, IL-10, TNF-α, OPN, and especially HGF and BAFF in response to the RPMI8226 cells. Moreover, the BMSCs of the MM patients significantly enhanced the production of sIL-6R by the RPMI8226 cells. DISCUSSION: Cytokines over-expressed by BMSCs of MM patients can function as growth factors for myeloma cells (IL-6, IL-10, HGF), migration stimulatory factors for tumor plasma cells (TNF-α, HGF), adhesion stimulatory factors (HGF, BAFF and OPN), stimulators of osteoclastogenesis (IL-6, TNF-α), and angiogenic factors (TNF-α). The results of this experiment strongly suggest that the BMSCs from MM patients differed in spontaneous and myeloma cell-induced production of cytokines, especially of HGF and BAFF, and these abnormalities were both primary and acquired by the BMSCs on contact with the MM cells. This in turn suggests the presence of an undefined, autocrine stimulation pathway resulting in a prolonged production of cytokines even in long-term cultures in vitro and in vivo. These abnormalities might provide optimal conditions for the proliferation and differentiation of residual tumor cells or their precursors in the affected bone marrow. Birkhäuser-Verlag 2008-05-30 2008-06 /pmc/articles/PMC2766495/ /pubmed/18512025 http://dx.doi.org/10.1007/s00005-008-0022-5 Text en © Birkhaueser 2008 |
spellingShingle | Original Article Zdzisińska, Barbara Bojarska-Junak, Agnieszka Dmoszyńska, Anna Kandefer-Szerszeń, Martyna Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells |
title | Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells |
title_full | Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells |
title_fullStr | Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells |
title_full_unstemmed | Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells |
title_short | Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells |
title_sort | abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to rpmi8226 myeloma cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766495/ https://www.ncbi.nlm.nih.gov/pubmed/18512025 http://dx.doi.org/10.1007/s00005-008-0022-5 |
work_keys_str_mv | AT zdzisinskabarbara abnormalcytokineproductionbybonemarrowstromalcellsofmultiplemyelomapatientsinresponsetorpmi8226myelomacells AT bojarskajunakagnieszka abnormalcytokineproductionbybonemarrowstromalcellsofmultiplemyelomapatientsinresponsetorpmi8226myelomacells AT dmoszynskaanna abnormalcytokineproductionbybonemarrowstromalcellsofmultiplemyelomapatientsinresponsetorpmi8226myelomacells AT kandeferszerszenmartyna abnormalcytokineproductionbybonemarrowstromalcellsofmultiplemyelomapatientsinresponsetorpmi8226myelomacells |